BRPI0516073A - comprimido de camada dupla e processo para a fabricação do mesmo - Google Patents

comprimido de camada dupla e processo para a fabricação do mesmo

Info

Publication number
BRPI0516073A
BRPI0516073A BRPI0516073-1A BRPI0516073A BRPI0516073A BR PI0516073 A BRPI0516073 A BR PI0516073A BR PI0516073 A BRPI0516073 A BR PI0516073A BR PI0516073 A BRPI0516073 A BR PI0516073A
Authority
BR
Brazil
Prior art keywords
double layer
manufacturing
tablet
layer tablet
angiotensin
Prior art date
Application number
BRPI0516073-1A
Other languages
English (en)
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim Internac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36145644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Internac filed Critical Boehringer Ingelheim Internac
Publication of BRPI0516073A publication Critical patent/BRPI0516073A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPRIMIDO DE CAMADA DUPLA E PROCESSO PARA A FABRICAçãO DO MESMO". A presente invenção refere-se a um comprimido de camada dupla que compreende uma primeira camada formulada para a liberação imediata do antagonista do receptor da angiotensina 11 telmisartan a partir de uma matriz de comprimido dissolvível e uma segunda camada formulada para a liberação imediata do inibidor da HMG-CoA redutase sinvastatina a partir de uma matriz de comprimido desintegrável ou desgastável.
BRPI0516073-1A 2004-10-12 2005-10-07 comprimido de camada dupla e processo para a fabricação do mesmo BRPI0516073A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04024239 2004-10-12
PCT/EP2005/010812 WO2006040085A2 (en) 2004-10-12 2005-10-07 Bilayer tablet

Publications (1)

Publication Number Publication Date
BRPI0516073A true BRPI0516073A (pt) 2008-08-19

Family

ID=36145644

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516073-1A BRPI0516073A (pt) 2004-10-12 2005-10-07 comprimido de camada dupla e processo para a fabricação do mesmo

Country Status (17)

Country Link
US (1) US20060078615A1 (pt)
EP (1) EP1802283A2 (pt)
JP (1) JP2008515838A (pt)
KR (1) KR20070064366A (pt)
CN (1) CN101052380A (pt)
AR (1) AR052775A1 (pt)
AU (1) AU2005293773A1 (pt)
BR (1) BRPI0516073A (pt)
CA (1) CA2578447A1 (pt)
EA (1) EA200700765A1 (pt)
EC (1) ECSP077381A (pt)
IL (1) IL182455A0 (pt)
NO (1) NO20071375L (pt)
TW (1) TW200628174A (pt)
UY (1) UY29160A1 (pt)
WO (1) WO2006040085A2 (pt)
ZA (1) ZA200701098B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CN101219120B (zh) * 2007-12-27 2011-02-23 江苏万邦生化医药股份有限公司 替米沙坦分散片及其制备方法
WO2009120052A1 (es) * 2008-03-24 2009-10-01 Laboratorios Pisa, S.A. De C.V. Composición farmacéutica con efecto sinérgico para el tratamiento de hipertensión arterial y dislipidemia
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
WO2010021473A2 (ko) * 2008-08-19 2010-02-25 한올제약주식회사 약제학적 제제
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
JP5776776B2 (ja) * 2011-08-05 2015-09-09 富士通株式会社 データ処理システム、およびデータ処理方法
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
ES3009527T3 (en) * 2014-07-25 2025-03-27 Laurent Pharmaceuticals Solid oral formulation of fenretinide
CN104739833A (zh) * 2015-02-16 2015-07-01 江苏欧信医药化工有限公司 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
CA2987071A1 (en) * 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
KR101883091B1 (ko) * 2017-01-18 2018-07-27 아주대학교산학협력단 안지오텐신 수용체 차단제 및 HMG-CoA 환원효소 억제제를 유효성분으로 함유하는 이층정 복합제제 및 이의 제조방법
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
HRP20040649B1 (en) * 2002-01-16 2012-12-31 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20050004193A1 (en) * 2003-01-16 2005-01-06 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
AU2005293773A1 (en) 2006-04-20
WO2006040085A2 (en) 2006-04-20
IL182455A0 (en) 2007-07-24
EA200700765A1 (ru) 2007-10-26
ZA200701098B (en) 2009-06-24
TW200628174A (en) 2006-08-16
NO20071375L (no) 2007-05-10
US20060078615A1 (en) 2006-04-13
WO2006040085A3 (en) 2007-03-15
JP2008515838A (ja) 2008-05-15
KR20070064366A (ko) 2007-06-20
ECSP077381A (es) 2007-05-30
CN101052380A (zh) 2007-10-10
AR052775A1 (es) 2007-04-04
UY29160A1 (es) 2006-05-31
EP1802283A2 (en) 2007-07-04
CA2578447A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
NO20071375L (no) Bilags tablett.
BRPI0517809A (pt) comprimido de camada dupla
CL2018003398A1 (es) Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).
NO20063997L (no) Tablett med flere lag
EP2086519A4 (en) COMPLEX COMPOSITION WITH CONTROLLED RELEASE WITH ANGIOTENSIN II RECEPTOR BLOCKERS AND HMG COA REDUCTASE INHIBITORS
GT200600194A (es) Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada
MX2009013971A (es) Derivado de sulfonamida de acido malonico novedoso y su uso farmaceutico.
ECSP099501A (es) Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
EP1951686A4 (en) CHINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PRODUCTION THEREOF
EP1879070A4 (en) COMPOSITION FOR RESISTING LAYERED FILM FORMATION TO FORM A PHOTO NETWORK-CURED RESISTANT LAYER FILM
BRPI0608505B8 (pt) comprimido sublingual revestido
ECSP088429A (es) Diarilureas para el tratamiento de la hipertensión pulmonar
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
ECSP10010160A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
MA30781B1 (fr) Inhibiteur de kinase
CR10336A (es) Compuestos organicos y sus usos
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
ECSP055695A (es) Proceso para la fabricacion de valsartan
UA101556C2 (uk) Комбіноване застосування інгібітора pde 4 та інгібітора hmg-coa-редуктази для профілактики або зцілювального лікування запального захворювання легенів
EP2036895A4 (en) HSP90 INHIBITOR
PA8571901A1 (es) Nueva composicion farmaceutica
CR9521A (es) Metodo novedoso de tratamiento de la hiperlipedemia
BRPI0509926A (pt) imidazóis
MA32933B1 (fr) Combinaison d'inhibiteurs de hspo90 et d'herceptine

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]